Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 629.58M P/E - EPS this Y 33.60% Ern Qtrly Grth -
Income -262.14M Forward P/E -2.76 EPS next Y 41.80% 50D Avg Chg 8.00%
Sales 59.61M PEG -0.48 EPS past 5Y - 200D Avg Chg -25.00%
Dividend N/A Price/Book 4.50 EPS next 5Y 9.80% 52W High Chg -63.00%
Recommedations 2.10 Quick Ratio 6.38 Shares Outstanding 114.97M 52W Low Chg 41.00%
Insider Own 2.50% ROA -38.12% Shares Float 74.79M Beta 1.14
Inst Own 95.84% ROE -175.79% Shares Shorted/Prior 19.26M/15.78M Price 10.25
Gross Margin 91.63% Profit Margin - Avg. Volume 1,262,433 Target Price 18.00
Oper. Margin -452.23% Earnings Date May 7 Volume 568,776 Change -3.03%
About Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Arcutis Biotherapeutics, Inc. News
04/10/24 Arcutis Appoints David Topper as Chief Financial Officer
04/08/24 Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?
04/05/24 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/01/24 Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
03/28/24 Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference
03/19/24 Arcutis Biotherapeutics, Inc. (ARQT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
03/19/24 Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?
03/18/24 Wall Street Analysts See a 54.78% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High?
03/11/24 Arcutis Promotes Todd Tucker to Chief Human Resources Officer
03/10/24 Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
03/09/24 New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
03/08/24 Peabody Energy, Citi Trends, and More Stocks See Action From Activist Investors
03/04/24 Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
03/04/24 Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting
03/01/24 Wall Street Analysts See a 58.85% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High?
03/01/24 Is Arcutis Biotherapeutics (ARQT) Outperforming Other Medical Stocks This Year?
03/01/24 Earnings Beat: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
02/29/24 Arcutis to Present at the TD Cowen 44th Annual Health Care Conference
02/29/24 Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2023 Earnings Call Transcript
02/29/24 Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues
ARQT Chatroom

User Image NobVega Posted - 3 hours ago

$ARQT Back in at $10.20. Still expecting big gains after earnings and update.

User Image nastento Posted - 4 hours ago

$ARQT safe money

User Image 85Thebrit Posted - 5 hours ago

$ARQT slight sign of stability here.. see how we fair by Friday. 😃

User Image zawojak Posted - 7 hours ago

$ARQT hold this gem don't sell for pennies

User Image PsychoNut Posted - 9 hours ago

$ARQT this war, inflation, fact we have 2 weeks oil reserves... huge fear factors. It doesn't need to get better out there. Just needs to stay the same, and everyone gets use to it.

User Image zawojak Posted - 1 day ago

$ARQT Company making money 💰💰💰

User Image PsychoNut Posted - 1 day ago

$ARQT futures are green? I call BS. Someone in power will f something up!

User Image PsychoNut Posted - 1 day ago

$ARQT just another day! Bah bah bah bah bah! ARGHHHHHH! NO MORE GROUNDHOGS DAY SH!T MARKET!

User Image Rhody27 Posted - 2 days ago

$ARQT could have been worse

User Image 85Thebrit Posted - 2 days ago

$ARQT just a blip in a long road to success, buy it up and look forward to earnings in May. 😃

User Image BugHunti Posted - 2 days ago

$VTYX next profit here $arqt

User Image AZNEWCASTLE Posted - 2 days ago

$ARQT This is such a great price to add. After upcoming earnings and July approval will be 13-14 SP. Time to add more!

User Image 85Thebrit Posted - 2 days ago

$ARQT

User Image JOEYD05 Posted - 2 days ago

$ARQT

User Image Bornjever Posted - 4 days ago

$ARQT earnings on May 7 should bring us a smile and then another approval in just mile PDUFA July 7 with more sales and profits coming our way

User Image CookieWatcher Posted - 4 days ago

$AKBA lol what is going on with Steve and Jack… this stock is going beyond $2 at least for sure. I remembered $ARQT went down a little from $3 to $2 after their FDA approval in December, and now it is $10….

User Image 85Thebrit Posted - 5 days ago

$ARQT you know it's bs with all those buy up's at 10.20 at the 4pm close..😅😂

User Image fdetrana Posted - 5 days ago

$ARQT thanks for the cheapies!!

User Image 85Thebrit Posted - 5 days ago

$ARQT hold for the May earnings ..just an absolutely ridiculous day today all over. Have a good weekend all 😁

User Image toddk18 Posted - 5 days ago

$ARQT Options manipulation playing a role most likely. Not the full picture but MM are doing what they do.

User Image toddk18 Posted - 5 days ago

$ARQT XBI is at a two month low. Bios and overall maket getting slammed. Arqt is still a quality name.

User Image 85Thebrit Posted - 5 days ago

$ARQT no buyers out there at these prices...REALLY!?!

User Image dekkoe Posted - 5 days ago

$ARQT there you have it, -10.

User Image Rhody27 Posted - 5 days ago

$ARQT the MMs want this under $10.00

User Image khanso Posted - 5 days ago

$ARQT where is the f’in bottom???

User Image 85Thebrit Posted - 5 days ago

$ARQT what a day...😬🤯😵‍💫

User Image nastento Posted - 5 days ago

$ARQT wrong😂 take a look at the bigger picture and look at thr market

User Image AdiDasRom Posted - 5 days ago

$ARQT No way

User Image nevermind889 Posted - 5 days ago

$ARQT why is this down 14%?

User Image Rhody27 Posted - 5 days ago

$ARQT this has to be connected to the conference yesterday. This is what happens when a company has a big miss on earnings.

Analyst Ratings
Needham Buy Apr 12, 24
Goldman Sachs Neutral Feb 28, 24
Mizuho Buy Feb 28, 24
Needham Buy Feb 28, 24
Mizuho Buy Feb 23, 24
Mizuho Buy Jan 3, 24
Mizuho Buy Jan 2, 24
Morgan Stanley Overweight Nov 13, 23
JonesTrading Hold Nov 8, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Burnett Patrick See Remarks See Remarks Jan 02 Sell 3.5408 1,325 4,692 57,032 01/03/24
Watanabe Todd Franklin See Remarks See Remarks May 31 Buy 6.38 1,463 9,334 515,145 12/01/23
Watanabe Todd Franklin See Remarks See Remarks May 31 Option 1.68 59,525 100,002 513,682 12/01/23
Matsuda Masaru See Remark See Remark Nov 18 Sell 1.98 1,850 3,663 46,634 11/21/23
Burnett Patrick See Remarks See Remarks Aug 18 Sell 7.05 1,605 11,315 58,357 08/22/23
Matsuda Masaru See Remark See Remark May 27 Sell 7.8 1,830 14,274 42,146 06/02/23
Welgus Howard G. Director Director Apr 17 Sell 13.97 8,500 118,745 165,825 04/18/23
Welgus Howard G. Director Director Apr 17 Option 1.68 8,500 14,280 174,325 04/18/23
Moore Matthew Richard See Remarks See Remarks Mar 02 Sell 16.17 1,610 26,034 11,690 03/06/23
Matsuda Masaru See Remarks See Remarks Mar 02 Sell 16.17 1,434 23,188 18,101 03/06/23
Burnett Patrick See Remarks See Remarks Mar 02 Sell 16.17 1,751 28,314 39,813 03/06/23
Watanabe Todd Franklin See Remarks See Remarks Feb 28 Sell 16.17 7,815 126,369 369,092 03/02/23
Burrows Scott L Chief Financial Offi.. Chief Financial Officer Feb 28 Sell 16.17 1,850 29,915 38,406 03/02/23
Lock Kenneth A. Chief Commercial Off.. Chief Commercial Officer Feb 28 Sell 16.17 2,368 38,291 43,260 03/02/23
OSBORNE DAVID W Chief Technical Offi.. Chief Technical Officer Feb 28 Sell 16.17 2,005 32,421 254,644 03/02/23
Welgus Howard G. Director Director Feb 15 Sell 16.98 8,500 144,330 165,825 02/21/23
Welgus Howard G. Director Director Feb 15 Option 1.68 8,500 14,280 174,325 02/21/23
Watanabe Todd Franklin See Remarks See Remarks Feb 13 Sell 17.02 1,000 17,020 376,907 02/15/23
Welgus Howard G. Director Director Jan 17 Sell 13.72 8,500 116,620 165,825 01/18/23
Welgus Howard G. Director Director Jan 17 Option 1.68 8,500 14,280 174,325 01/18/23
Burrows Scott L Chief Financial Offi.. Chief Financial Officer Sep 16 Option 1.6806 5,000 8,403 40,256 09/20/22
Watanabe Todd Franklin President and CEO President and CEO Sep 07 Sell 21.51 1,000 21,510 381,907 09/09/22
Welgus Howard G. Director Director Aug 15 Sell 24.7981 6,000 148,789 174,208 08/17/22
Watanabe Todd Franklin President and CEO President and CEO Aug 05 Option 1.68 2,500 4,200 654,371 08/09/22
Watanabe Todd Franklin President and CEO President and CEO Aug 05 Sell 24.74 2,500 61,850 651,871 08/09/22
Frazier Life Sciences VIII, L.... 10% Owner 10% Owner Aug 05 Buy 20.00 250,000 5,000,000 8,684,232 08/09/22
Turney Patricia A. SVP, Operations SVP, Operations Mar 23 Option 6.52 15,331 99,958 46,444 08/04/22
Welgus Howard G. Director Director Jul 18 Sell 24.3956 6,000 146,374 180,208 07/18/22
OSBORNE DAVID W Chief Technical Offi.. Chief Technical Officer Jul 08 Sell 25.4144 2,197 55,835 256,649 07/12/22
Watanabe Todd Franklin President and CEO President and CEO Jul 08 Option 1.68 7,087 11,906 658,958 07/12/22
Watanabe Todd Franklin President and CEO President and CEO Jul 08 Sell 25.28 13,500 341,280 651,871 07/12/22
Watanabe Todd Franklin President and CEO President and CEO Jul 06 Sell 22.07 1,000 22,070 658,284 07/07/22
Watanabe Todd Franklin President and CEO President and CEO May 05 Sell 21.76 1,000 21,760 658,667 05/05/22
Welgus Howard G. Director Director May 02 Option 1.13 2,500 2,825 184,396 05/03/22
Welgus Howard G. Director Director May 02 Sell 20.44 2,500 51,100 181,896 05/03/22
OSBORNE DAVID W Chief Technical Offi.. Chief Technical Officer Apr 21 Sell 20.4243 2,197 44,872 257,229 04/21/22
ORBIMED ADVISORS LLC 10% Owner 10% Owner Apr 06 Sell 20.69 878,200 18,169,958 451,086 04/08/22
Watanabe Todd Franklin President and CEO President and CEO Apr 05 Sell 21.43 1,000 21,430 659,667 04/05/22
Welgus Howard G. Director Director Apr 01 Option 0.58 7,500 4,350 189,396 04/01/22
Welgus Howard G. Director Director Apr 01 Sell 20.02 7,500 150,150 181,896 04/01/22
Watanabe Todd Franklin President and CEO President and CEO Mar 09 Sell 17.00 300 5,100 660,667 03/11/22
Watanabe Todd Franklin President and CEO President and CEO Mar 03 Option 1.68 700 1,176 661,667 03/07/22
Watanabe Todd Franklin President and CEO President and CEO Mar 03 Sell 16.8 3,259 54,751 660,967 03/07/22
Burnett Patrick See Remarks See Remarks Mar 03 Sell 16.65 1,011 16,833 43,039 03/07/22
Lock Kenneth A. Chief Commercial Off.. Chief Commercial Officer Mar 03 Sell 16.65 1,023 17,033 44,011 03/07/22
Burrows Scott L Chief Financial Offi.. Chief Financial Officer Mar 03 Sell 16.65 303 5,045 35,256 03/07/22
Turney Patricia A. SVP, Operations SVP, Operations Mar 03 Sell 16.65 1,023 17,033 31,113 03/07/22
OSBORNE DAVID W Chief Technical Offi.. Chief Technical Officer Mar 03 Sell 16.65 856 14,252 259,426 03/07/22
Watanabe Todd Franklin President and CEO President and CEO Feb 09 Option 1.68 1,000 1,680 595,779 02/11/22
Watanabe Todd Franklin President and CEO President and CEO Feb 09 Sell 17 1,000 17,000 594,779 02/11/22